Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Rises 19 Percent to Lead BCW Index

Agilent Rises 19 Percent to Lead BCW Index

Shares in Agilent rose 19 percent over the five-day trading period ended Tuesday, outgaining by far the other 14 companies in the BCW Index. Investors reacted favorably to the firm's announcement this week that it would divest its semiconductor unit and restructure the firm (see related article).

On the other end of the spectrum was Stratagene, which lost 10.7 percent of its stock's value over the past week. The firm didn't announce any news, and investors were likely pulling back some of the 20 percent rise the shares had experienced over the previous two weeks.

Overall, the Index gained .4 percent, beating the Nasdaq Biotech Index, which dropped .5 percent, the broader Nasdaq, which lost .1 percent, and the Dow Jones Industrial Average, which declined 1 percent for the week.

BioCommerce Week’s Index to the
Diversified Molecular Biology Tools Companies
Company
Ticker
Current Price
(
August 16, 2005)
Last Price
(
August 9 2005)
% Change
Agilent
A
30.48
25.58
19.16
Applied Biosystems
ABI
20.69
21.15
-2.17
Beckman
BEC
54
52.95
1.98
Bio-Rad
BIO
55.62
55.75
-0.23
Bruker
BRKR
4.24
4.1
3.41
GE
GE
33.88
34.14
-0.76
Harvard Bio
HBIO
3.1
3.09
0.32
Invitrogen
IVGN
84.81
85.7
-1.04
Molecular Devices
MDCC
20.06
20.36
-1.47
PerkinElmer
PKI
20.31
20.32
-0.05
Qiagen
QGEN
12.62
12.86
-1.87
Sigma
SIAL
61.86
62.01
-0.24
Strategene
STGN
9.11
10.2
-10.69
Thermo
TMO
28.71
28.9
-0.66
Waters
WAT
44.49
44.91
-0.94
Index Average  
32.27
32.13
0.41
The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.